Kodu・Aktsiate loetelu・Alvotech SA

Alvotech SA

Avatud

SektorTervishoid

4.05 -0.74

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.98

Max

4.13

Põhinäitajad
By Trading Economics
Sissetulek	110M 1M
Müük	-60M 106M
P/E Sektori keskmine	42.4 57.002
Aktsiakasum	-0.09
Kasumimarginaal	0.973
Töötajad	1,279
EBITDA	167M 52M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	-2.2% downside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	19. aug 2026

Turustatistika
By TradingEconomics
Turukapital	261M 1.3B
Eelmine avamishind	4.79
Eelmine sulgemishind	4.05

Uudiste sentiment

By Acuity

40%

60%

134 / 340 Pingereas Healthcare

Alvotech SA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. aug 2026, 20:06 UTC

Alvotech SA shares are higher during Thursday's session, continuing an upward trend since Wednesday's close, trading above its 20-day moving average.

12. aug 2026, 19:31 UTC

Alvotech SA shares are trading higher, reflecting market optimism after recent inflation data showed core CPI aligned with forecasts. No specific company news was identified.

11. aug 2026, 19:26 UTC

News

Alvotech's Reykjavik facility receives Voluntary Action Indicated status from the FDA, allowing advancement of multiple Biologics License Applications. Shares are trading higher.

10. aug 2026, 20:06 UTC

News

Alvotech SA will release its financial results for the first half of 2026 on August 19, after the U.S. market close. Shares are little changed.

6. aug 2026, 20:06 UTC

Alvotech SA shares are higher today, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

5. aug 2026, 19:56 UTC

Alvotech SA shares are lower during Wednesday's session, continuing a decline since Tuesday's close amid broader market trends and falling oil prices.

4. aug 2026, 19:52 UTC

Alvotech SA shares are higher today, supported by declining crude oil prices easing inflation concerns. The stock remains above its 20-day moving average.

3. aug 2026, 19:51 UTC

Alvotech SA shares are lower today, reflecting a sharp decline despite a brief rebound earlier in the session. No specific news was identified for the drop.

31. juuli 2026, 21:02 UTC

Alvotech SA shares declined in after-market trading, reversing six days of gains. No specific news was identified to explain the price movement.

30. juuli 2026, 20:10 UTC

Alvotech SA shares are higher during Thursday's session, reflecting broader market movements amid mixed economic signals and maintaining a position above the 20-day moving average.

29. juuli 2026, 19:04 UTC

News

Social Media

Alvotech SA's FDA inspection results in a Voluntary Action Indicated classification. Shares are trading higher as the company advances its biosimilar pipeline.

28. juuli 2026, 19:56 UTC

Alvotech SA shares are higher today, reaching a high of 6.17%. The stock remains below its 20-day moving average with no specific news identified.

27. juuli 2026, 19:31 UTC

Alvotech SA shares are higher today, rebounding from an earlier session low. This follows a positive trend since Friday's close amid declining oil prices.

24. juuli 2026, 19:51 UTC

Alvotech SA shares are lower today, continuing a trend of weakness amid broader market pressures and three consecutive lower daily closes.

22. juuli 2026, 18:31 UTC

Alvotech SA shares are lower, continuing a decline since Tuesday. Broader market sentiment is impacted by geopolitical tensions and rising crude oil prices.

21. juuli 2026, 19:16 UTC

Alvotech SA shares are higher during Tuesday's session amid a broader market recovery, driven by renewed interest in AI stocks and upcoming tech earnings.

20. juuli 2026, 19:31 UTC

Alvotech SA shares are lower today, with no specific news identified. Broader market weakness includes a decline in the US 10Y Treasury Bond index.

Võrdlus sarnastega

Hinnamuutus

Alvotech SA Prognoos

Hinnasiht

By TipRanks

-2.2% langus

12 kuu keskmine prognoos

Keskmine 4 USD -2.2%

Kõrge 4 USD

Madal 4 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Alvotech SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Alvotech SA aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

134 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Alvotech SA

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.